Phase II Pilot Study of Hyper-CVAD Plus Rituximab for Previously Untreated Mantle Cell Lymphoma
Phase 2
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Mantle Cell Lymphoma
Both
Mantle Cell Lymphoma
Trial Information
Phase II Pilot Study of Hyper-CVAD Plus Rituximab for Previously Untreated Mantle Cell Lymphoma
rituximab and modified hyperfractionated cyclophosphamide, vincristine doxorubicin,
dexamethasone (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab
maintenance therapy consisting of four weekly doses every six months for two years
Inclusion Criteria:
- Untreated mantle cell lymphoma
Exclusion Criteria:
- Pregnant or breast feeding
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Complete Response Rate to Induction Therapy
Outcome Time Frame:
10/31/2004
Safety Issue:
No
Authority:
United States: Institutional Review Board
Study ID:
HO00401
NCT ID:
NCT00581854
Start Date:
June 2000
Completion Date:
March 2010
Related Keywords:
- Mantle Cell Lymphoma
- untreated mantle cell lymphoma
- Lymphoma
- Lymphoma, Mantle-Cell
Name | Location |
|---|---|
| UWCCC | Madison, Wisconsin 53792 |
